

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jeffrey Hubbell, Jason Schense, Andreas Zisch and Heike Hall

Serial No.: Continuation of 10/024,918                      Art Unit:              Not Yet Assigned

Filed: August 27, 2003    Examiner:              Not Yet Assigned

For: *ENZYME-MEDIATED MODIFICATION OF FIBRIN FOR TISSUE  
ENGINEERING*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including eleven (11) pages of Form PTO-1449. All of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 10/024,918, filed December 18, 2001, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

### U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,613,665	09-23-1986	Larm	536/20
4,810,784	03-07-19	Larm	536/20
5,100,668	03-31-1992	Edelman et al.	424/422
5,504,001	04-02-1996	Foster	435/219
5,561,982	10-08-1996	Tunkel et al	62/5
5,693,341	12-01-1997	Schroeder et al.	424/488
6,331,422	12-18-2001	Hubbell, et al.	435/193

### Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 89/00051	01-12-1989	Cytrx Biopool Ltd.	PCT
WO 90/05177	05-17-1990	Syntro Corporation	PCT
WO 92/22312	12-23-1992	Jonas Wadstrom	PCT
WO 95/05396	02-23-1995	Zymogenetics, Inc.	PCT
WO 95/23611	09-08-1995	Protein Polymer Technologies, Inc.	PCT

### Publications

ADAMS, et al., "Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis," *Genes & Development* 13:295-306 (1999).

BAUMGARTNER, et al., "Constitutive expression of phVEGF<sub>165</sub> after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia," *Circulation* 97:1114-1123 (1998).

BESSON, et al., "Synthetic Peptide Substrates for a Conductimetric Assay of *Pseudomonas aeruginosa* Elastase," *Analytical BioChemistry*, Article No. 0232, 237:216-223 (1996).

BLAESS, et al., "Structural analysis of the sixth immunoglobulin-like domain of mouse neural cell adhesion molecule L1 and its interactions with  $\alpha_v\beta_3$ ,  $\alpha_{IIb}\beta_3$ , and  $\alpha_5\beta_1$  integrins," *J Neurochem* 71:2615-2625 (1998).

BORRAJO, et al., "Derivatized Cyclodextrins as Peptidomimetics: Influence on Neurite Growth," *Bioorganic and Medicinal Chemistry Letters* 7(9):1185-1190 (1997).

BROOKS, et al., "Requirement of vascular integrin  $\alpha_v\beta_3$  for angiogenesis," *Science* 264:569-571 (1994).

BRUCKNER, "EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains," *Neuron* 22:511-524 (1999).

CALDERWOOD, et al., "Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling," *J Biol Chem* 275:22607-22610 (2000).

CAMARATA, et al., "Sustained Release of Nerve Growth Factor from Biodegradable Polymer Microspheres," *Neurosurgery* 30(3) 313-319 (1992).

CARDIN, et al., "Molecular Modeling of Protein-Glycosaminoglycan Interactions," *Arteriosclerosis* 9:21-32 (1989).

CONOVER, et al., "Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone," *Nature Neuroscience* 3(11):1091-3324 (2000).

COOMBS, et al., "Directing Sequence-specific Proteolysis to New Targets," *Journal of Biological Chemistry* 273(8):4323-4328 (1998).

DALVA, et al., "EphB receptors interact with NMDA receptors and regulate excitatory synapse formulation," *Cell* 103:945-956 (2000).

DEDHAR & HANNIGAN, "Integrin cytoplasmic interactions and bidirectional transmembrane signaling," *Current Opinion in Cell Biology* 8:657-669 (1996).

DIMILLA, et al., "Mathematical model for the effects of adhesion and mechanics on cell migration speed," *Biophysical Journal* 60:15-37(1991).

DINBERGS, et al., "Cellular Response to Transforming Growth factor- $\beta$ 1 and Basic Fibroblast Growth factor Depends on release Kinetics and Extracellular Matrix Interactions," *Journal of Biological Chemistry* 271(47):29822-29829 (1996).

DOWNS, et al., "Calcium Alginate Beads as a Slow-Release System for Delivering Angiogenic Molecules in Vivo and In Vitro," *Journal of Cellular Physiology* 152:422-429 (1992).

EDELMAN, et al., "Basic Fibroblast Growth Factor Enhances the Coupling of Intimal Hyperplasia and Proliferation of Vasa Vasorum in Injured Rat Arteries," *The American Society for Clinical Investigation, Inc.* 89:465-473 (1992).

EDELMAN, et al., "Controlled and modulated release of basic fibroblast growth factor," *Biomaterials* 12:619-626 (1991).

EDELMAN, et al., "Perivascular and intravenous administration of basic fibroblast growth factor: Vascular and solid organ deposition," *Proc. Natl. Acad. Sci USA* 90:1513-1517 (1993).

EDGAR, et al., "The heparin-binding domain of laminin is responsible for its effects on neurite outgrowth and neuronal survival," *EMBO Journal* 3(7):1463-1468 (1984).

ELICEIRI & CHERESH, "The role of  $\alpha v$  integrins during angiogenesis: insights into potential mechanisms of action and clinical development," *Journal of Clinical Investigation* 103:1227-1230 (1999).

FASOL, et al., "Experimental use of a modified fibrin glue to induce site-directed angiogenesis from the aorta to the heart," *Journal of Thoracic and Cardiovascular Surgery* 107:1432-9 (1994).

FELDING-HABERMANN, et al., "A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple and platelet integrins," *J Cell Biol* 139:1567-1581 (1997).

FENG, et al., "Roles for ephrins in positionally selective synaptogenesis between motor neurons and muscle fibers," *Neuron* 25:295-306 (2000).

FERRARA & ALITALO, "Clinical applications of angiogenic growth factors and their inhibitors," *Nature Medicine* 5:1359-1364 (1999).

FERRARA, "Molecular and biological properties of vascular endothelial growth factor," *J Mol Med* 77:527-543 (1999).

FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease," *Nature Medicine* 1:27-31 (1995).

GALE, et al., "Ephrin-B2 selectivity marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells," *Developmental Biology* 230:151-160 (2001).

GÖTZ, et al., "Neurotrophin-6 is a new member of the nerve growth factor family," *Letter to Nature* 372:266-269(1994).

GRIESLER, et al., "Enhanced endothelial of expanded polyethrafluoroethylene grafts by fibroblast growth factor type 1 pretreatment," *Surgery* 112:244-255 (1992).

HALL, "Molecular properties of fibrin-based matrices for promotion of angiogenesis in vitro," *Microvascular Research* 62:315-326 (2001).

HALL, et al., "Trimerization of cell adhesion molecule L1 mimics clustered L1 expression on the cell surface: Influence on L1-Ligand interactions and on promotion of neurite outgrowth," *J of Neurochemistry* 75:336-346 (2000).

HAMMOND, et al., "Management of coronary artery disease: Therapeutic options in patients with diabetes," *JACC* 36:355-65 (2000).

HARADA, et al., "Basic Fibroblast Growth Factor Improves Myocardial Function in chronically Ischemic Porcine Hearts," *The American Society for Clinical Investigation, Inc.* 94:623-630 (1994).

HATA, et al., "Binding of Lipoprotein Lipase to Heparin," *Journal of Biological Chemistry* 268(12):8447-8457 (1993).

HAUGEN, et al., "Central and Peripheral Neurite Outgrowth Differs in Preference for Heparin-Binding versus Integrin-Binding Sequences," *Journal of Neuroscience* 12(6):2034-2042 (1992).

HERBERT, et al., "Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels," *Journal Biomed Mater Res.* 40:551-559 (1998).

HERBERT, et al., "Effects of Fibrinolysis on Neurite Growth From Dorsal Root Ganglia Cultured in Two- and Three-Dimensional Fibrin Gels," *The Journal of Comparative Neurology* 365:380-391 (1996).

HOULE & JOHNSON, "Nerve growth factor (NGF)-treated nitrocellulose enhances and directs the regeneration of adult rat dorsal root axons through intraspinal neural tissue transplants," *Neuroscience Letters* 103:17-23 (1989).

HUBBELL, "Bioactive biomaterials," *Curr Opin Biotech* 10:123-129 (1999).

HUMPHRIES, "Integrin activation: the link between ligand binding and signal transduction," *Curr Opin Cell Biol* 8:632-640 (1996).

ILAN, et al., "Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis," *J of Cell Science* 111:3621-3631 (1998).

INGER & FOLKMAN, "How does extracellular matrix control capillary morphogenesis?" *Cell* 58:803-805 (1989).

KALLAPUR, et al., "The Neural Cell Adhesion Molecule (NCAM) Heparin Binding Domain Binds to Cell Surface Heparan Sulfate Proteoglycans," *Journal of Neuroscience Research* 33:538-548 (1992).

KANEDA, et al., "Midkine, a Heparin-Binding Growth/Differentiation Factor, Exhibits Nerve Cell Adhesion and Guidance for Neurite Outgrowth in Vitro," *Journal of Biochemistry* 119:1150-1156 (1996).

KANG, et al., "Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by fibroblast growth factor-1 plus heparin delivered from glue suspensions," *Surgery* 118:280-287 (1995).

KIGUCHI, et al., "Altered Expression of Epidermal Growth factor Receptor Ligands in Tumor Promoter-Treated Mouse Epidermis and in Primary Mouse Skin Tumors Induced by an Initiation-Promotion Protocol," *Molecular Carcinogenesis* 22:73-83 (1998).

KINOSAKI, et al., "Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF)," *Biochemical Biophysics Acta* 1384:93-102(1998).

KLEINMAN, et al., "The Laminins: A Family of Basement Membrane Glycoproteins Important in Cell Differentiation and Tumor Metastases," *Vitamins and Hormones* 47:161-186 (1993).

LEE, et al., "Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: Development of a sensitive electrophoretic approach," *Biochemistry* 88:2768-2772 (1991).

LIN, et al., "Purification and Initial Characterization of Rat B49 Glial Cell Line-Derived Neurotrophic Factor," *Journal of Neurochemistry* 758-768 (1994).

LOPEZ, et al., "Basic Fibroblast Growth Factor in a Porcine Model of Chronic Myocardial Ischemia: A Comparison of Angiographic, Echocardiographic and Coronary Flow Parameters," *The Journal of Pharmacology and Experimental Therapeutics* 282(1):385-390 (1996).

LOPEZ, et al., "Short Communication, Local Perivascular Administration of Basic Fibroblast Growth Factor: Drug Delivery and Toxicological Evaluation," *Drug Metabolism and Disposition* 24(8):922-924 (1995).

LORSORDO, et al., "Gene therapy for myocardial angiogenesis. Initial clinical results with direct myocardial injection of phVEGF<sub>165</sub> as sole therapy for myocardial ischemia," *Circulation* 98:2800-2804 (1998).

LYON, et al., "The Interaction of the Transforming Growth Factor- $\beta$ s with Heparin/Heparan Sulfate is Isoform-specific," *The Journal of Biological Chemistry* 272(29):18000-18006 (1997).

MARTIN, "Laminin and Other Basement Membrane Components," *Annual Review of Cellular Biology* 3:57-85 (1987).

MASSIA, et al., "An RGD Spacing of 440 nm is Sufficient for Integrin  $\alpha$ 1 $\beta$ 3-mediated Fibroblast Spreading and 140 nm for Focal contact and Stress Fiber Formation," *The Journal of Cell Biology* 114(5):1089-110 (1991).

MAYSINGER, et al., "Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions," *Neuroscience Letters* 140:71-74 (1992).

MCCAFFREY, et al., "Transforming Growth Factor- $\beta$ 1 Is a Heparin-Binding Protein: Identification of Putative Heparin-Binding Regions and Isolation of Heparins with Varying Affinity for TGF- $\beta$ 1," *Journal of Cellular Physiology* 152:430-440 (1992).

MONTGOMERY, et al., "Human neural cell adhesion molecule L1 and Rat homologue NILE are ligands for integrin  $\alpha_v\beta_3$ ," *J Cell Biol* 132:475-485 (1996).

NEHLS & HERRMANN, "The configuration of fibrin clots determine capillary morphogenesis and endothelial cell migration," *Microvascular Research* 51:347-364 (1996).

NETZEL-ARNETT, et al., "Sequence Specificities of Human Fibroblast and Neutrophil Collagenases," *Journal of Biological Chemistry* 266(11):6747-6755 (1991).

NOLO, et al., "Developmentally Regulated Neurite Outgrowth Response from Dorsal root Ganglion Neurons to Heparin-binding Growth-associated Molecule (HB-GAM) and the expression of HB-GAM on the Targets of the Developing Dorsal Root Ganglion Neurites," *European Journal of Neuroscience* 8:1658-1665 (1996).

PEPPER, et al., "Angiogenesis: a paradigm for balanced extracellular proteolysis cell migration and morphogenesis," *Enzyme Protein* 49:138-162 (1996).

POWELL, et al., "Controlled Release of nerve growth factor from a polymeric implant," *Brain Research* 515:309-311 (1990).

PRESTA, et al., "Structure-Function Relationship of Basic Fibroblast Growth Factor: Site-Directed Mutagenesis of a Putative Heparin-Binding and Receptor-Binding Region," *Biochemical and Biophysical Research Communications* 185(3):1098-1107 (1992).

REDDI, "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and Regeneration," *Nature Biotechnology* 16:247-252 (1998).

ROGERS, et al., "Neuron-Specific Interactions with Two Neurite-Promoting Fragments of Fibronectin," *Journal of Neuroscience* 5(2):369-378 (1985).

ROSENGART, et al., "Angiogenesis Gene Therapy. Phase I assessment of direct intramyocardial administration of an adenovirus expressing phVEGF<sub>165</sub> cDNA to individuals with clinically significant severe coronary artery disease," *Circulation* 100:468-474 (1999).

RUOSLAHTI & ENGVALL, "Perspectives series: Cell adhesion in vascular biology," *J Clin Invest* 99:1149-1152 (1997).

SAKATA & AOKI, et al., "Cross-linking of  $\alpha_2$ -plasmin inhibitor to fibrin by fibrin-stabilizing factor," *J Clin Invest* 65:290-297 (1980).

SAKIYAMA, et al., "Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering,"

SAKIYAMA-ELBERT & HUBBELL, "Development of Fibrin Derivatives for Controlled Release of Heparin-Binding Growth Factors," *Journal of Controlled Release* 65:389-402 (2000).

SCHENSE & HUBBELL, "Cross-Linking Exogenous Bifunctional Peptides into Fibrin Gels with Factor XIIIa," *Bioconjugate Chemistry* 10(1):75-81 (1999).

SCHENSE, et al., "Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension," *Nature Biotechnology* 18:415-419 (2000).

SCHROEDER-TEFFT et al., "Collagen and heparin matrices for growth factor delivery," *Journal of Controlled Release* 49:291-298 (1997).

SELLKE, et al, "Enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation," *Basic FGF* H1303-1311 (1994).

SHIN, et al., "Expression of EphrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and of adult neovascularization," *Developmental Biology* 230:139-150 (2001).

SHIREMAN, et al., "Modulation of vascular cell growth by local cytokine delivery from fibrin glue suspensions," *J Vasc Surg* 19:852-62 (1999).

SHUMACHER, et al., "Induction of neoangiogenesis in ischemic myocardium by human growth factors," *Circulation* 97:645-650 (1998).

SMITH, et al., "Rapid Identification of Highly Active and Selective Substrates for Stromelysin and Matrilysin Using Bacteriophage Peptide Display Libraries," *Journal of Biological Chemistry* 270(12):6440-6449 (1995).

SPILLMAN, et al., "Defining the Interleukin-8-Binding Domain of Heparan Sulfate," *Journal of Biological Chemistry* 273(25):15487-15493 (1998).

STEFFEN, et al., "Characterization of Cell-Associated and Soluble Forms of Connective Tissue Growth Factor (CTFG) Produced by Fibroblast Cells in Vitro," *Growth Factors* 15:199-213 (1998).

STEIN, et al., "Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses," *Genes & Development* 12:667-678 (1998).

STUDIER, et al., "Use of T7 RNA Polymers to Direct expression of Cloned Genes," *Methods in Enzymology* 185:60-89 (1990).



TAKAGI, et al., "Amino Acid Sequence Studies on the Chain of Human Fibrinogen. Location of Four Plasmin Attack Points and a Covalent cross-linking Site," *Biochemistry* 14(23):5149-5156 (1975).

TAKESHITA, et al., "Therapeutic Angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model," *J Clin Invest* 93:662-670 (1994).

TASHIRO, et al., "A Synthetic Peptide containing the IKVAV Sequence from the A Chain of Laminin Mediates Cell Attachment, Migration, and Neurite Outgrowth," *Journal of Biological Chemistry* 264(27):16174-16182 (1989).

TESSLER, et al., "Heparin Modulates the Interaction of VEGF 165 with Soluble and Cell Associated flk-1 Receptors," *Journal of Biological Chemistry* 269(17):12456-12461 (1994).

THOMPSON, et al., "Site-directed neovessel formation in vivo," *Science* 241:1349-1352 (1988).

TYLER-CROSS, et al., "Heparin binding domain peptides of antithrombin III: Analysis by isothermal titration calorimetry and circular dichroism spectroscopy," *Protein Science* 3:620-627 (1994).

WANG, et al., "Molecular distinction and angiogenesis interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4," *Cell* 93:741-753 (1998).

WEATHERFORD, et al., "Vascular endothelial growth factor and heparin in a biologic glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition," *Surgery* 433-439 (1996).

YAMADA, "Adhesive Recognition Sequences," *The Journal of Biological Chemistry* 266(20):12809-12812 (1991).


YANISH-PERRON, et al., "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors," *Gene* 33:103-119 (1985).

ZUCKER, et al., "Platelet Factor 4: Production, Structure, and Physiologic and Immunologic Action," *Proceedings for the Society of Experimental Biology and Medicine* 198:693-702 (1991).

**Remarks**

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

  
\_\_\_\_\_  
Patrea L. Pabst  
Reg. No. 31,284

Dated: August 27, 2003

HOLLAND & KNIGHT LLP  
One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400  
404-817-8473  
FAX 404-817-8588  
www.hklaw.com  
ATL1 #591450 v1

Substitute for form 1449A/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	Continuation of 10/024,918
				Filing Date	August 27, 2003
				First Named Inventor	Jeffrey Hubbell
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	CIT 2606 CIP CON
Sheet	1	of	11		

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		WO	89/00051		Cytrx Biopool Ltd.	01-12-1989		
		WO	90/05177		Syntro Corporation	05-17-1990		
		WO	92/22312		Jonas Wadstrom	12-23-1992		
		WO	95/05396		Zymogenetics, Inc.	02-23-1995		
		WO	95/23611		Protein Polymer Technologies, Inc.	09-08-1995		

Examine Signature		Date Considered	
-------------------	--	-----------------	--

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	Continuation of 10/024,918		
		Filing Date	August 27, 2003		
		First Named Inventor	Jeffrey Hubbell		
		Group Art Unit			
Examiner Name					
Sheet	2	of	11	Attorney Docket Number	CIT 2606 CIP CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ADAMS, et al., "Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis," <i>Genes &amp; Development</i> 13:295-306 (1999).	
		BAUMGARTNER, et al., "Constitutive expression of phVEGF <sub>165</sub> after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia," <i>Circulation</i> 97:1114-1123 (1998).	
		BESSON, et al., "Synthetic Peptide Substrates for a Conductimetric Assay of Pseudomonas aeruginosa Elastase," <i>Analytical Biochemistry</i> , Article No. 0232, 237:216-223 (1996).	
		BLAESS, et al., "Structural analysis of the sixth immunoglobulin-like domain of mouse neural cell adhesion molecule L1 and its interactions with $\alpha_5\beta_3$ , $\alpha 11\beta_3$ , and $\alpha 5\beta 1$ integrins," <i>J Neurochem</i> 71:2615-2625 (1998).	
		BORRAJO, et al., "Derivatized Cyclodextrins as Peptidomimetics: Influence on Neurite Growth," <i>Bioorganic and Medicinal Chemistry Letters</i> 7(9):1185-1190 (1997).	
		BRUCKNER, "EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains," <i>Neuron</i> 22:511-524 (1999).	
		BROOKS, et al., "Requirement of vascular integrin $\alpha_5\beta_3$ for angiogenesis," <i>Science</i> 264:569-571 (1994).	
		CALDERWOOD, et al., "Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling," <i>J Biol Chem</i> 275:22607-22610 (2000).	
		CAMARATA, et al., "Sustained Release of Nerve Growth Factor from Biodegradable Polymer Microspheres," <i>Neurosurgery</i> 30(3) 313-319 (1992).	
		CARDIN, et al., "Molecular Modeling of Protein-Glycosaminoglycan Interactions," <i>Arteriosclerosis</i> 9:21-32 (1989).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Applicant Number	Continuation of 10/024,918
		Filing Date	August 27, 2003
		First Named Inventor	Jeffrey Hubbell
		Group Art Unit	
		Examiner Name	
Sheet 3 of 11	Attorney Docket Number	CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		CONOVER, et al., "Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone," <i>Nature Neuroscience</i> 3(11):1091-3324 (2000).	
		COOMBS, et al., "Directing Sequence-specific Proteolysis to New Targets," <i>Journal of Biological Chemistry</i> 273(8):4323-4328 (1998).	
		DALVA, et al., "EphB receptors interact with NMDA receptors and regulate excitatory synapse formulation," <i>Cell</i> 103:945-956 (2000).	
		DEDHAR & HANNIGAN, "Integrin cytoplasmic interactions and bidirectional transmembrane signaling," <i>Current Opinion in Cell Biology</i> 8:657-669 (1996).	
		DIMILLA, et al., "Mathematical model for the effects of adhesion and mechanics on cell migration speed," <i>Biophysical Journal</i> 60:15-37(1991).	
		DINBERGS, et al., "Cellular Response to Transforming Growth factor-β1 and Basic Fibroblast Growth factor Depends on release Kinetics and Extracellular Matrix Interactions," <i>Journal of Biological Chemistry</i> 271(47):29822-29829 (1996).	
		DOWNS, et al., "Calcium Alginate Beads as a Slow-Release System for Delivering Angiogenic Molecules in Vivo and In Vitro," <i>Journal of Cellular Physiology</i> 152:422-429 (1992).	
		EDELMAN, et al., "Basic Fibroblast Growth Factor Enhances the Coupling of Intimal Hyperplasia and Proliferation of Vasa Vasorum in Injured Rat Arteries," <i>The American Society for Clinical Investigation, Inc.</i> 89:465-473 (1992).	
		EDELMAN, et al., "Controlled and modulated release of basic fibroblast growth factor," <i>Biomaterials</i> 12:619-626 (1991).	
		EDELMAN, et al., "Perivascular and intravenous administration of basic fibroblast growth factor: Vascular and solid organ deposition," <i>Proc. Natl. Acad. Sci USA</i> 90:1513-1517 (1993).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Continuation of 10/024,918
		Filing Date	August 27, 2003
		First Named Inventor	Jeffrey Hubbell
		Group Art Unit	
		Examiner Name	
Sheet 4 of 11	Attorney Docket Number	CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		EDGAR, et al., "The heparin-binding domain of laminin is responsible for its effects on nuerite outgrowth and neuronal survival," <i>EMBO Journal</i> 3(7):1463-1468 (1984).	
		ELICEIRI & CHERESH, "The role of $\alpha v$ integrins during angiogenesis: insights into potential mechanisms of action and clinical development," <i>Journal of Clinical Investigation</i> 103:1227-1230 (1999).	
		FASOL, et al., "Experimental use of a modified fibrin glue to induce site-directed angiogenesis from the aorta to the heart," <i>Journal of Thoracic and Cardiovascular Surgery</i> 107:1432-9 (1994).	
		FELDING-HABERMANN, et al., "A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple and platelet integrins," <i>J Cell Biol</i> 139:1567-1581 (1997).	
		FENG, et al., "Roles for ephrins in positionally selective synaptogenesis between motor neurons and muscle fibers," <i>Neuron</i> 25:295-306 (2000).	
		FERRARA & ALITALO, "Clinical applications of angiogenic growth factors and their inhibitors," <i>Nature Medicine</i> 5:1359-1364 (1999).	
		FERRARA, "Molecular and biological properties of vascular endothelial growth factor," <i>J Mol Med</i> 77:527-543 (1999).	
		FOLKMAN, "Angiogenesis in cancer, vascular , rheumatoid and other disease," <i>Nature Medicine</i> 1:27-31 (1995).	
		GALE, et al., "Ephrin-B2 selectivity marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells," <i>Developmental Biology</i> 230:151-160 (2001).	
		GÖTZ, et al., "Neurotrophin-6 is a new member of the nerve growth factor family," <i>Letter to Nature</i> 372:266-269(1994).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				C mplet If Kn wn	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Applicati n Number	
				Continuati n f 10/024,918	
				Filing Date	
				August 27, 2003	
				First Named Inventor	
				Jeffrey Hubbell	
Group Art Unit					
Examiner Name					
Sheet	5	of	11	Attorney Docket Number	
				CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		GRIESLER, et al., "Enhanced endothelial of expanded polyethrafluoroethylene grafts by fibroblast growth factor type 1 pretreatment," <i>Surgery</i> 112:244-255 (1992).	
		HALL, "Molecular properties of fibrin-based matrices for promotion of angiogenesis in vitro," <i>Microvascular Research</i> 62:315-326 (2001).	
		HALL, et al., "Trimerization of cell adhesion molecule L1 mimics clustered L1 expression on the cell surface: Influence on L1-Ligand interactions and on promotion of neurite outgrowth," <i>J of Neurochemistry</i> 75:336-346 (2000).	
		HAMMOND, et al., "Management of coronary artery disease: Therapeutic options in patients with diabetes," <i>JACC</i> 36:355-65 (2000).	
		HARADA, et al., "Basic Fibroblast Growth Factor Improves Myocardial Function in chronically Ischemic Porcine Hearts," <i>The American Society for Clinical Investigation, Inc.</i> 94:623-630 (1994).	
		HATA, et al., "Binding of Lipoprotein Lipase to Heparin," <i>Journal of Biological Chemistry</i> 268(12):8447-8457 (1993).	
		HAUGEN, et al., "Central and Peripheral Neurite Outgrowth Differs in Preference for Heparin-Binding versus Integrin-Binding Sequences," <i>Journal of Neuroscience</i> 12(6):2034-2042 (1992).	
		HERBERT, et al., "Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels," <i>Journal Biomed Mater Res.</i> 40:551-559 (1998).	
		HERBERT, et al., "Effects of Fibrinolysis on Neurite Growth From Dorsal Root Ganglia Cultured in Two- and Three-Dimensional Fibrin Gels," <i>The Journal of Comparative Neurology</i> 365:380-391 (1996).	
		HOULE & JOHNSON, "Nerve growth factor (NGF)-treated nitrocellulose enhances and directs the regeneration of adult rat dorsal root axons through intraspinal neural tissue transplants," <i>Neuroscience Letters</i> 103:17-23 (1989).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Continuation of 10/024,918
		Filing Date	August 27, 2003
		First Named Inventor	Jeffrey Hubbell
		Group Art Unit	
		Examiner Name	
Sheet 6 of 11	Attorney Docket Number	CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		HUBBELL, "Bioactive biomaterials," <i>Curr Opin Biotech</i> 10:123-129 (1999).	
		HUMPHRIES, "Integrin activation: the link between ligand binding and signal transduction," <i>Curr Opin Cell Biol</i> 8:632-640 (1996).	
		ILAN, et al., "Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis," <i>J of Cell Science</i> 111:3621-3631 (1998).	
		INGER & FOLKMAN, "How does extracellular matrix control capillary morphogenesis?" <i>Cell</i> 58:803-805 (1989).	
		KALLAPUR, et al., "The Neural Cell Adhesion Molecule (NCAM) Heparin Binding Domain Binds to Cell Surface Heparan Sulfate Proteoglycans," <i>Journal of Neuroscience Research</i> 33:538-548 (1992).	
		KANEDA, et al., "Midkine, a Heparin-Binding Growth/Differentiation Factor, Exhibits Nerve Cell Adhesion and Guidance for Neurite Outgrowth in Vitro," <i>Journal of Biochemistry</i> 119:1150-1156 (1996).	
		KANG, et al., "Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by fibroblast growth factor-1 plus heparin delivered from glue suspensions," <i>Surgery</i> 118:280-287 (1995).	
		KIGUCHI, et al., "Altered Expression of Epidermal Growth factor Receptor Ligands in Tumor Promoter-Treated Mouse Epidermis and in Primary Mouse Skin Tumors Induced by an Initiation-Promotion Protocol," <i>Molecular Carcinogenesis</i> 22:73-83 (1998).	
		KINOSAKI, et al., "Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF)," <i>Biochemical Biophysics Acta</i> 1384:93-102(1998).	
		KLEINMAN, et al., "The Laminins: A Family of Basement Membrane Glycoproteins Important in Cell Differentiation and Tumor Metastases," <i>Vitamins and Hormones</i> 47:161-186 (1993).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Completeness of Information	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Continuation of 10/024,918
		Filing Date	August 27, 2003
		First Named Inventor	Jeffrey Hubbell
		Group Art Unit	
		Examiner Name	
Sheet 7 of 11	Attorney Docket Number	CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		LEE, et al., "Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: Development of a sensitive electrophoretic approach," <i>Biochemistry</i> 88:2768-2772 (1991).	
		LIN, et al., "Purification and Initial Characterization of Rat B49 Glial Cell Line-Derived Neurotrophic Factor," <i>Journal of Neurochemistry</i> 758-768 (1994).	
		LOPEZ, et al., "Basic Fibroblast Growth Factor in a Porcine Model of Chronic Myocardial Ischemia: A Comparison of Angiographic, Echocardiographic and Coronary Flow Parameters," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 282(1):385-390 (1996).	
		LOPEZ, et al., "Short Communication, Local Perivascular Administration of Basic Fibroblast Growth Factor: Drug Delivery and Toxicological Evaluation," <i>Drug Metabolism and Disposition</i> 24(8):922-924 (1995).	
		LORSORDO, et al., "Gene therapy for myocardial angiogenesis. Initial clinical results with direct myocardial injection of phVEGF <sub>165</sub> as sole therapy for myocardial ischemia," <i>Circulation</i> 98:2800-2804 (1998).	
		LYON, et al., "The Interaction of the Transforming Growth Factor- $\beta$ s with Heparin/Heparan Sulfate is Isoform-specific," <i>The Journal of Biological Chemistry</i> 272(29):18000-18006 (1997).	
		MARTIN, "Laminin and Other Basement Membrane Components," <i>Annual Review of Cellular Biology</i> 3:57-85 (1987).	
		MASSIA, et al., "An RGD Spacing of 440 nm is Sufficient for Integrin $\alpha$ 5 $\beta$ 1-mediated Fibroblast Spreading and 140 nm for Focal contact and Stress Fiber Formation," <i>The Journal of Cell Biology</i> 114(5):1089-110 (1991).	
		MAYSINGER, et al., "Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions," <i>Neuroscience Letters</i> 140:71-74 (1992).	
		MCCAFFREY, et al., "Transforming Growth Factor- $\beta$ 1 is a Heparin-Binding Protein: Identification of Putative Heparin-Binding Regions and Isolation of Heparins with Varying Affinity for TGF- $\beta$ 1," <i>Journal of Cellular Physiology</i> 152:430-440 (1992).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Continuation of 10/024,918
		Filing Date	August 27, 2003
		First Named Inventor	Jeffrey Hubbell
		Group Art Unit	
		Examiner Name	
Sheet 8 of 11	Attorney Docket Number	CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		MONTGOMERY, et al., "Human neural cell adhesion molecule L1 and Rat homologue NILE are ligands for integrin $\alpha_v\beta_3$ ," <i>J Cell Biol</i> 132:475-485 (1996).	
		NEHLS & HERRMANN, "The configuration of fibrin clots determine capillary morphogenesis and endothelial cell migration," <i>Microvascular Research</i> 51:347-364 (1996).	
		NETZEL-ARNETT, et al., "Sequence Specificities of Human Fibroblast and Neutrophil Collagenases," <i>Journal of Biological Chemistry</i> 266(11):6747-6755 (1991).	
		NOLO, et al., "Developmentally Regulated Neurite Outgrowth Response from Dorsal root Ganglion Neurons to Heparin-binding Growth-associated Molecule (HB-GAM) and the expression of HB-GAM on the Targets of the Developing Dorsal Root Ganglion Neurites," <i>European Journal of Neuroscience</i> 8:1658-1665 (1996).	
		PEPPER, et al., "Angiogenesis: a paradigm for balanced extracellular proteolysis cell migration and morphogenesis," <i>Enzyme Protein</i> 49:138-162 (1996).	
		POWELL, et al., "Controlled Release of nerve growth factor from a polymeric implant," <i>Brain Research</i> 515:309-311 (1990).	
		PRESTA, et al., "Structure-Function Relationship of Basic Fibroblast Growth Factor: Site-Directed Mutagenesis of a Putative Heparin-Binding and Receptor-Binding Region," <i>Biochemical and Biophysical Research Communications</i> 185(3):1098-1107 (1992).	
		REDDI, "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and Regeneration," <i>Nature Biotechnology</i> 16:247-252 (1998).	
		ROGERS, et al., "Neuron-Specific Interactions with Two Neurite-Promoting Fragments of Fibronectin," <i>Journal of Neuroscience</i> 5(2):369-378 (1985).	
		ROSENGART, et al., "Angiogenesis Gene Therapy. Phase I assessment of direct intramyocardial administration of an adenovirus expressing phVEGF <sub>165</sub> cDNA to individuals with clinically significant severe coronary artery disease," <i>Circulation</i> 100:468-474 (1999).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Applicant Number	Continuation of 10/024,918
		Filing Date	August 27, 2003
		First Named Inventor	Jeffrey Hubbell
		Group Art Unit	
		Examiner Name	
Sheet 9 of 11	Attorney Docket Number	CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		RUOSLAHTI & ENGVALL, "Perspectives series: Cell adhesion in vascular biology," <i>J Clin Invest</i> 99:1149-1152 (1997).	
		SAKATA & AOKI, et al., "Cross-linking of $\alpha_2$ -plasmin inhibitor to fibrin by fibrin-stabilizing factor," <i>J Clin Invest</i> 65:290-297 (1980).	
		SAKIYAMA, et al., "Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering."	
		SAKIYAMA-ELBERT & HUBBELL, "Development of Fibrin Derivatives for Controlled Release of Heparin-Binding Growth Factors," <i>Journal of Controlled Release</i> 65:389-402 (2000).	
		SCHENSE & HUBBELL, "Cross-Linking Exogenous Bifunctional Peptides into Fibrin Gels with Factor XIIIa," <i>Bioconjugate Chemistry</i> 10(1):75-81 (1999).	
		SCHENSE, et al., "Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension," <i>Nature Biotechnology</i> 18:415-419 (2000).	
		SCHROEDER-TEFFT et al., "Collagen and heparin matrices for growth factor delivery," <i>Journal of Controlled Release</i> 49:291-298 (1997).	
		SELLKE, et al, "Enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation," <i>Basic FGF</i> H1303-1311 (1994).	
		SHIN, et al., "Expression of EphrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and of adult neovascularization," <i>Developmental Biology</i> 230:139-150 (2001).	
		SHIREMAN, et al., "Modulation of vascular cell growth by local cytokine delivery from fibrin glue suspensions," <i>J Vasc Surg</i> 19:852-62 (1999).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Compleat if Kn wn	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	
				Continuati n f 10/024,918	
				Filing Date	
				August 27, 2003	
				First Named Inventor	
				Jeffrey Hubbell	
Group Art Unit					
Examiner Name					
Sheet	10	of	11	Attorney Docket Number	
				CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		SHUMACHER, et al., "Induction of neoangiogenesis in ischemic myocardium by human growth factors," <i>Circulation</i> 97:645-650 (1998).	
		SMITH, et al., "Rapid Identification of Highly Active and Selective Substrates for Stromelysin and Matrilysin Using Bacteriophage Peptide Display Libraries," <i>Journal of Biological Chemistry</i> 270(12):6440-6449 (1995).	
		SPILLMAN, et al., "Defining the Interleukin-8-Binding Domain of Heparan Sulfate," <i>Journal of Biological Chemistry</i> 273(25):15487-15493 (1998).	
		STEFFEN, et al., "Characterization of Cell-Associated and Soluble Forms of Connective Tissue Growth Factor (CTFG) Produced by Fibroblast Cells in Vitro," <i>Growth Factors</i> 15:199-213 (1998).	
		STEIN, et al., "Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses," <i>Genes &amp; Development</i> 12:667-678 (1998).	
		STUDIER, et al., "Use of T7 RNA Polymers to Direct expression of Cloned Genes," <i>Methods in Enzymology</i> 185:60-89 (1990).	
		TAKAGI, et al., "Amino Acid Sequence Studies on the Chain of Human Fibrinogen. Location of Four Plasmin Attack Points and a Covalent cross-linking Site," <i>Biochemistry</i> 14(23):5149-5156 (1975).	
		TAKESHITA, et al., "Therapeutic Angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model," <i>J Clin Invest</i> 93:662-670 (1994).	
		TASHIRO, et al., "A Synthetic Peptide containing the IKVAV Sequence from the A Chain of Laminin Mediates Cell Attachment, Migration, and Neurite Outgrowth," <i>Journal of Biological Chemistry</i> 264(27):16174-16182 (1989).	
		TESSLER, et al., "Heparin Modulates the Interaction of VEGF 165 with Soluble and Cell Associated flk-1 Receptors," <i>Journal of Biological Chemistry</i> 269(17):12456-12461 (1994).	

Examiner's Signature		Date Considered	
-------------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Compl t If Kn wn	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Applicati n Number	
				Continuati n f 10/024,918	
				Filing Date	
				August 27, 2003	
				First Named Inventor	
				Jeffrey Hubbell	
Group Art Unit					
Examiner Name					
Sheet	11	of	11	Attorney Docket Number	
				CIT 2606 CIP CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		THOMPSON, et al., "Site-directed neovessel formation in vivo," <i>Science</i> 241:1349-1352 (1988).	
		TYLER-CROSS, et al., "Heparin binding domain peptides of antithrombin III: Analysis by isothermal titration calorimetry and circular dichroism spectroscopy," <i>Protein Science</i> 3:620-627 (1994).	
		WANG, et al., "Molecular distinction and angiogenesis interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4," <i>Cell</i> 93:741-753 (1998).	
		WEATHERFORD, et al., "Vascular endothelial growth factor and heparin in a biologic glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition," <i>Surgery</i> 433-439 (1996).	
		YAMADA, "Adhesive Recognition Sequences," <i>The Journal of Biological Chemistry</i> 266(20):12809-12812 (1991).	
		YANISH-PERRON, et al., "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors," <i>Gene</i> 33:103-119 (1985).	
		ZUCKER, et al., "Platelet Factor 4: Production, Structure, and Physiologic and Immunologic Action," <i>Proceedings for the Society of Experimental Biology and Medicine</i> 198:693-702 (1991).	

Examiner's Signature		Date Considered	
-------------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

